A novel
strontium salt compound
strontium fructose 1, 6-diphosphate (
FDP-Sr) has been proved to have highly effective for bone loss via dual effects of stimulating bone formation and suppressing bone absorption. In the present study, metabolomic approach was used to identify and study potential
biomarkers associated with the effect and safety of
FDP-Sr. The metabolomic profiles of bone loss induced by
estrogen deficiency in a rat model was described to attain a system-level map of the shift on the metabolic response in plasma using GC/TOF-MS, after
FDP-Sr was orally administered at the dose of 110 mg/kg/day for the prevention and 220 mg/kg/day for the treatment. Meanwhile, bone turnover
biomarkers and bone mineral density were investigated to identify the specific changes of potential anti-
osteoporosis effects of
FDP-Sr. The differences in metabolic profiles between
osteoporosis rats and
FDP-Sr treated rats were well observed by the partial least squares-discriminant analysis (PLS-DA) to the MS spectra. Some metabolites including
homocysteine,
arachidonic acid,
alanine, and
hydroxyproline, which significantly changed during
osteoporosis progression could be effectively reversed after
FDP-Sr
therapy. Of course some metabolites such as
uric acid,
glyceric acid,
octadecadienoic acid,
docosahexaenoic acid,
oleic acid, and
hexadecanoic acid were not found to reverse significantly after
FDP-Sr administration. These results delineated the
FDP-Sr effects-related metabolic alterations in the bone loss rats, suggesting that metabonomic analysis could provide helpful information on the new potential
biomarkers relating to the mechanism of anti-
osteoporosis action and side effects of
FDP-Sr against
estrogen deficiency induced bone loss.